Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
Article
PubMed
Google Scholar
Howlader N, Altekruse SF, Li CI, Chen VW, Clarke CA, Ries LA, Cronin KA: US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst 2014;106(5).
Rugo HS, Rumble RB, Macrae E, Barton DL, Connolly HK, Dickler MN, Fallowfield L, Fowble B, Ingle JN, Jahanzeb M, et al. Endocrine Therapy for hormone receptor-positive metastatic breast cancer: american society of clinical oncology guideline. J Clin Oncol Off J Am Soc Clin Oncol. 2016;34(25):3069–103.
Article
CAS
Google Scholar
Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, Harbeck N, Aguilar Lopez B, Barrios CH, Bergh J, et al. 4th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 4)†. Ann Oncol Off J Eur Soc Med Oncol. 2018;29(8):1634–57.
Article
CAS
Google Scholar
Spring LM, Wander SA, Andre F, Moy B, Turner NC, Bardia A. Cyclin-dependent kinase 4 and 6 inhibitors for hormone receptor-positive breast cancer: past, present, and future. Lancet (London, England). 2020;395(10226):817–27.
Article
CAS
Google Scholar
Turner NC, Ro J, André F, Loi S, Verma S, Iwata H, Harbeck N, Loibl S, Huang Bartlett C, Zhang K, et al. Palbociclib in hormone-receptor-positive advanced breast cancer. N Engl J Med. 2015;373(3):209–19.
Article
CAS
PubMed
Google Scholar
Li Y, Li W, Gong C, Zheng Y, Ouyang Q, Xie N, Qu Q, Ge R, Wang B. A multicenter analysis of treatment patterns and clinical outcomes of subsequent therapies after progression on palbociclib in HR+/HER2- metastatic breast cancer. Ther Adv Med Oncol. 2021;13:17588359211022890.
CAS
PubMed
PubMed Central
Google Scholar
Herrera-Abreu MT, Palafox M, Asghar U, Rivas MA, Cutts RJ, Garcia-Murillas I, Pearson A, Guzman M, Rodriguez O, Grueso J, et al. Early adaptation and acquired resistance to CDK4/6 inhibition in estrogen receptor-positive breast cancer. Can Res. 2016;76(8):2301–13.
Article
CAS
Google Scholar
Pandey K, An HJ, Kim SK, Lee SA, Kim S, Lim SM, Kim GM, Sohn J, Moon YW. Molecular mechanisms of resistance to CDK4/6 inhibitors in breast cancer: a review. Int J Cancer. 2019;145(5):1179–88.
Article
CAS
PubMed
PubMed Central
Google Scholar
Turner NC, Liu Y, Zhu Z, Loi S, Colleoni M, Loibl S, DeMichele A, Harbeck N, André F, Bayar MA, et al. Cyclin E1 expression and palbociclib efficacy in previously treated hormone receptor-positive metastatic breast cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2019;37(14):1169–78.
Article
CAS
Google Scholar
Del Re M, Bertolini I, Crucitta S, Fontanelli L, Rofi E, De Angelis C, Diodati L, Cavallero D, Gianfilippo G, Salvadori B, et al. Overexpression of TK1 and CDK9 in plasma-derived exosomes is associated with clinical resistance to CDK4/6 inhibitors in metastatic breast cancer patients. Breast Cancer Res Treat. 2019;178(1):57–62.
Article
PubMed
CAS
Google Scholar
Darrigues L, Pierga JY, Bernard-Tessier A, Bièche I, Silveira AB, Michel M, Loirat D, Cottu P, Cabel L, Dubot C, et al. Circulating tumor DNA as a dynamic biomarker of response to palbociclib and fulvestrant in metastatic breast cancer patients. Breast Cancer Res BCR. 2021;23(1):31.
Article
CAS
PubMed
Google Scholar
O’Leary B, Finn RS, Turner NC. Treating cancer with selective CDK4/6 inhibitors. Nat Rev Clin Oncol. 2016;13(7):417–30.
Article
CAS
PubMed
Google Scholar
Miller TW, Balko JM, Fox EM, Ghazoui Z, Dunbier A, Anderson H, Dowsett M, Jiang A, Smith RA, Maira SM, et al. ERα-dependent E2F transcription can mediate resistance to estrogen deprivation in human breast cancer. Cancer Discov. 2011;1(4):338–51.
Article
CAS
PubMed
PubMed Central
Google Scholar
Fang H, Huang D, Yang F, Guan X. Potential biomarkers of CDK4/6 inhibitors in hormone receptor-positive advanced breast cancer. Breast Cancer Res Treat. 2018;168(2):287–97.
Article
CAS
PubMed
Google Scholar
Patel HK, Tao N, Lee KM, Huerta M, Arlt H, Mullarkey T, Troy S, Arteaga CL, Bihani T. Elacestrant (RAD1901) exhibits anti-tumor activity in multiple ER+ breast cancer models resistant to CDK4/6 inhibitors. Breast Cancer Res BCR. 2019;21(1):146.
Article
CAS
PubMed
Google Scholar
Sieuwerts AM, Inda MA, Smid M, van Ooijen H, van de Stolpe A, Martens JWM, Verhaegh WFJ. ER and PI3K pathway activity in primary ER positive breast cancer is associated with progression-free survival of metastatic patients under first-line tamoxifen. Cancers. 2020;12(4):802.
Article
CAS
Google Scholar
Sighoko D, Liu J, Hou N, Gustafson P, Huo D. Discordance in hormone receptor status among primary, metastatic, and second primary breast cancers: Biological difference or misclassification? Oncologist. 2014;19(6):592–601.
Article
PubMed
PubMed Central
Google Scholar
Schrijver W, Suijkerbuijk KPM, van Gils CH, van der Wall E, Moelans CB, van Diest PJ. Receptor conversion in distant breast cancer metastases: a systematic review and meta-analysis. J Natl Cancer Inst. 2018;110(6):568–80.
Article
PubMed
Google Scholar
van Es SC, van der Vegt B, Bensch F, Gerritse S, van Helden EJ, Boon E, Angus L, Overbosch J, der Menke-van Houven VO, Verheul HM, et al. Decalcification of breast cancer bone metastases with EDTA does not affect ER PR and HER2 results. Am J Surg Pathol. 2019;43(10):1355–60.
Article
PubMed
Google Scholar
Lindström LS, Yau C, Czene K, Thompson CK, Hoadley KA, Van’t Veer LJ, Balassanian R, Bishop JW, Carpenter PM, Chen YY, et al. Intratumor heterogeneity of the estrogen receptor and the long-term risk of fatal breast cancer. J Natl Cancer Inst. 2018;110(7):726–33.
Article
PubMed
PubMed Central
Google Scholar
Liao GJ, Clark AS, Schubert EK, Mankoff DA. 18F-fluoroestradiol PET: current status and potential future clinical applications. J Nucl Med. 2016;57(8):1269–75.
Article
CAS
PubMed
Google Scholar
Kurland BF, Wiggins JR, Coche A, Fontan C, Bouvet Y, Webner P, Divgi C, Linden HM. Whole-body characterization of estrogen receptor status in metastatic breast cancer with 16α-18f-fluoro-17β-estradiol positron emission tomography: meta-analysis and recommendations for integration into clinical applications. Oncologist. 2020;25(10):835–44.
Article
CAS
PubMed
PubMed Central
Google Scholar
Liu C, Xu X, Yuan H, Zhang Y, Zhang Y, Song S, Yang Z. Dual Tracers of 16α-[18F]fluoro-17β-Estradiol and [18F]fluorodeoxyglucose for prediction of progression-free survival after fulvestrant therapy in patients with HR+/HER2- metastatic breast cancer. Front Oncol. 2020;10: 580277.
Article
PubMed
PubMed Central
Google Scholar
He M, Liu C, Shi Q, Sun Y, Zhang Y, Xu X, Yuan H, Zhang Y, Liu Y, Liu G, et al. The predictive value of early changes in (18) F-fluoroestradiol positron emission tomography/computed tomography during fulvestrant 500 mg therapy in patients with estrogen receptor-positive metastatic breast cancer. Oncologist. 2020;25(11):927–36.
Article
CAS
PubMed
PubMed Central
Google Scholar
Kurland BF, Peterson LM, Lee JH, Schubert EK, Currin ER, Link JM, Krohn KA, Mankoff DA, Linden HM. Estrogen receptor binding (18F-FES PET) and glycolytic activity (18F-FDG PET) predict progression-free survival on endocrine therapy in patients with ER+ breast cancer. Clin Cancer Res. 2017;23(2):407–15.
Article
CAS
PubMed
Google Scholar
Yang Z, Sun Y, Xu X, Zhang Y, Zhang J, Xue J, Wang M, Yuan H, Hu S, Shi W, et al. The assessment of estrogen receptor status and its intratumoral heterogeneity in patients with breast cancer by using 18F-fluoroestradiol PET/CT. Clin Nucl Med. 2017;42(6):421–7.
Article
PubMed
Google Scholar
van Kruchten M, Glaudemans A, de Vries EFJ, Schröder CP, de Vries EGE, Hospers GAP. Positron emission tomography of tumour [(18)F]fluoroestradiol uptake in patients with acquired hormone-resistant metastatic breast cancer prior to oestradiol therapy. Eur J Nucl Med Mol Imaging. 2015;42(11):1674–81.
Article
PubMed
PubMed Central
CAS
Google Scholar
Chae SY, Ahn SH, Kim SB, Han S, Lee SH, Oh SJ, Lee SJ, Kim HJ, Ko BS, Lee JW, et al. Diagnostic accuracy and safety of 16α-[(18)F]fluoro-17β-oestradiol PET-CT for the assessment of oestrogen receptor status in recurrent or metastatic lesions in patients with breast cancer: a prospective cohort study. Lancet Oncol. 2019;20(4):546–55.
Article
CAS
PubMed
Google Scholar
Liu C, Gong C, Liu S, Zhang Y, Zhang Y, Xu X, Yuan H, Wang B, Yang Z. (18)F-FES PET/CT influences the staging and management of patients with newly diagnosed estrogen receptor-positive breast cancer: a retrospective comparative study with (18)F-FDG PET/CT. Oncologist. 2019;24(12):e1277–85.
Article
CAS
PubMed
PubMed Central
Google Scholar
Boellaard R, Delgado-Bolton R, Oyen WJ, Giammarile F, Tatsch K, Eschner W, Verzijlbergen FJ, Barrington SF, Pike LC, Weber WA, et al. FDG PET/CT: EANM procedure guidelines for tumour imaging: version 2.0. Eur J Nucl Med Mol Imaging. 2015;42(2):328–54.
Article
CAS
PubMed
Google Scholar
Li Y, Liu C, Wang B, Hu X, Gong C, Zhao Y, Xie Y, Zhang Y, Song S, Yang Z, et al. Prediction of pretreatment 18F-FDG-PET/CT parameters on the outcome of first-line therapy in patients with metastatic breast cancer. Int J Gen Med. 2021;14:1797–809.
Article
PubMed
PubMed Central
Google Scholar
Wang Y, Ayres KL, Goldman DA, Dickler MN, Bardia A, Mayer IA, Winer E, Fredrickson J, Arteaga CL, Baselga J, et al. (18)F-Fluoroestradiol PET/CT measurement of estrogen receptor suppression during a Phase I trial of the novel estrogen receptor-targeted therapeutic GDC-0810: using an imaging biomarker to guide drug dosage in subsequent trials. Clin Cancer Res. 2017;23(12):3053–60.
Article
CAS
PubMed
Google Scholar
Lu Y, Tong Y, Chen X, Shen K. Association of biomarker discrepancy and treatment decision, disease outcome in recurrent/metastatic breast cancer patients. Front Oncol. 2021;11: 638619.
Article
PubMed
PubMed Central
Google Scholar
Sperduto PW, Mesko S, Li J, Cagney D, Aizer A, Lin NU, Nesbit E, Kruser TJ, Chan J, Braunstein S, et al. Estrogen/progesterone receptor and HER2 discordance between primary tumor and brain metastases in breast cancer and its effect on treatment and survival. Neuro Oncol. 2020;22(9):1359–67.
Article
CAS
PubMed
PubMed Central
Google Scholar
van Kruchten M, Glaudemans AW, de Vries EF, Beets-Tan RG, Schröder CP, Dierckx RA, de Vries EG, Hospers GA. PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma. J Nucl Med. 2012;53(2):182–90.
Article
PubMed
CAS
Google Scholar
Boers J, Venema CM, de Vries EFJ, Glaudemans A, Kwee TC, Schuuring E, Martens JWM, Elias SG, Hospers GAP, Schröder CP. Molecular imaging to identify patients with metastatic breast cancer who benefit from endocrine treatment combined with cyclin-dependent kinase inhibition. Eur J Cancer (Oxford England: 1990). 2020;126:11–20.
Article
CAS
Google Scholar
Gong C, Ma G, Hu X, Zhang Y, Wang Z, Zhang J, Zhao Y, Li Y, Xie Y, Yang Z, et al. Pretreatment (18)F-FDG uptake heterogeneity predicts treatment outcome of first-line chemotherapy in patients with metastatic triple-negative breast cancer. Oncologist. 2018;23(10):1144–52.
Article
CAS
PubMed
PubMed Central
Google Scholar
Zhao Y, Liu C, Zhang Y, Gong C, Li Y, Xie Y, Wu B, Yang Z, Wang B. Prognostic value of tumor heterogeneity on 18F-FDG PET/CT in HR+HER2- metastatic breast cancer patients receiving 500 mg fulvestrant: a retrospective study. Sci Rep. 2018;8(1):14458.
Article
PubMed
PubMed Central
CAS
Google Scholar
Gradishar WJ, Moran MS, Abraham J, Aft R, Agnese D, Allison KH, Anderson B, Burstein HJ, Chew H, Dang C, et al. Breast Cancer version 3202, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw JNCCN. 2022;20(6):691–722.
Article
PubMed
Google Scholar
Burstein HJ, Somerfield MR, Barton DL, Dorris A, Fallowfield LJ, Jain D, Johnston SRD, Korde LA, Litton JK, Macrae ER et al: Endocrine treatment and targeted therapy for hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: ASCO guideline update. J Clin Oncol Off J Am Soc Clin Oncol 2021;Jco2101392.
Hickey TE, Selth LA, Chia KM, Laven-Law G, Milioli HH, Roden D, Jindal S, Hui M, Finlay-Schultz J, Ebrahimie E, et al. The androgen receptor is a tumor suppressor in estrogen receptor-positive breast cancer. Nat Med. 2021;27(2):310–20.
Article
CAS
PubMed
Google Scholar
Jacene H, Liu M, Cheng SC, Abbott A, Dubey S, McCall K, Young D, Johnston M, Van den Abbeele AD, Overmoyer B. Imaging androgen receptors in breast cancer with (18)F-Fluoro-5α-dihydrotestosterone PET: a pilot study. J Nucl Med. 2022;63(1):22–8.
Article
CAS
PubMed
PubMed Central
Google Scholar
Bonelli M, Terenziani R, Zoppi S, Fumarola C, La Monica S, Cretella D, Alfieri R, Cavazzoni A, Digiacomo G, Galetti M, et al. Dual inhibition of CDK4/6 and PI3K/AKT/mTOR signaling impairs energy metabolism in MPM cancer cells. Int J Mol Sci. 2020;21(14):5165.
Article
CAS
PubMed Central
Google Scholar